| An Epidemiological Study of Genetic Risk Factors for Prostate Cancer in African-American and Caucasian Males (NCT00342771) | National Cancer Institute (NCI) | 2004-11-08 |
| Identification of Prostate Cancer Genes (NCT00342784) | National Human Genome Research Institute (NHGRI) | 2004-11-08 |
| Study of Oxaliplatin and Taxotere in Prostate Cancer (NCT00260611) | University of Pittsburgh | 2004-11-01 |
| Phase 1 Trial of Ipilimumab and GVAX in Patients With Metastatic Castration-resistant Prostate Cancer (NCT01510288) | Amsterdam UMC, location VUmc | 2004-11-01 |
| Immunization With NY-ESO-1 Protein Combined With CpG 7909 in Patients With Prostate Cancer (NCT00292045) | Ludwig Institute for Cancer Research | 2004-10-27 |
| Hormone Therapy and Docetaxel or Hormone Therapy Alone in Treating Patients With Metastatic Prostate Cancer (NCT00104715) | UNICANCER | 2004-10-18 |
| Study of Peri-Operative Docetaxel Plus Laparoscopic Radical Prostatectomy in Prostate Cancer Patients (NCT00127088) | Gustave Roussy, Cancer Campus, Grand Paris | 2004-10-01 |
| Hypofractionated Radiotherapy (55 Gy/16 Fractions/4 Weeks) for Localized Prostate Cancer (NCT00129025) | Alberta Health services | 2004-10-01 |
| Bortezomib With or Without Hormone Therapy in Treating Patients With Relapsed Prostate Cancer (NCT00103376) | Medical University of South Carolina | 2004-10-01 |
| Androgen Deprivation Therapy in Treating Patients With Prostate Cancer (NCT00110162) | Peter MacCallum Cancer Centre, Australia | 2004-10-01 |
| Study of D-Methadone in Patients With Chronic Pain (NCT00588640) | Memorial Sloan Kettering Cancer Center | 2004-10-01 |
| Casodex/Zoladex Biomarkers in Localised Prostate Cancer (NCT00293696) | Tampere University | 2004-10-01 |
| Epoetin Alfa With or Without Dexamethasone in Treating Fatigue and Anemia in Patients With Hormone-Refractory Prostate Cancer (NCT00060398) | Eastern Cooperative Oncology Group | 2004-09-29 |
| NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine (NCT00199849) | Ludwig Institute for Cancer Research | 2004-09-27 |
| Follow-Up Study of Subjects Previously Enrolled in Poxviral Vector Gene Transfer Studies (NCT00451022) | National Cancer Institute (NCI) | 2004-09-13 |
| Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data (NCT00341939) | National Cancer Institute (NCI) | 2004-09-07 |
| Neoadjuvant Therapy With Docetaxel and Ketoconazole in Patients With High-Risk Prostate Cancer: A Pilot Study (NCT00870714) | Kansas City Veteran Affairs Medical Center | 2004-09-01 |
| Short-course Hypofractionated Radiotherapy for Localized Prostate Cancer (NCT00126165) | Alberta Health services | 2004-09-01 |
| Magnetic Resonance Imaging of Lymph Nodes Using Ferumoxytol in Patients With Primary Prostate or Breast Cancer (NCT00087347) | Massachusetts General Hospital | 2004-09-01 |
| Calcitriol, Mitoxantrone, and Prednisone in Treating Patients With Metastatic Prostate Cancer (NCT00182741) | OHSU Knight Cancer Institute | 2004-09-01 |
| A Phase II Study of BAY 43-9006 (Sorafenib) in Metastatic, Androgen-Independent Prostate Cancer (NCT00090545) | National Cancer Institute (NCI) | 2004-09-01 |
| Radiation Therapy, Docetaxel, and Hormone Therapy in High-Risk Locally Advanced Metastasized Prostate Cancer (NCT00482807) | University of Nebraska | 2004-08-31 |
| Sorafenib in Treating Patients With Metastatic or Recurrent Prostate Cancer (NCT00093457) | NCIC Clinical Trials Group | 2004-08-10 |
| Lycopene in Preventing Prostate Cancer in Healthy Participants (NCT00093561) | University of Illinois at Chicago | 2004-08-01 |
| Intravenous CG7870 in Combination With Docetaxel in Patients With Metastatic Hormone-Refractory Prostate Cancer (NCT00103428) | Cell Genesys | 2004-08-01 |
| Postoperative Telerounding: A Multi-Center Prospective Randomized Assessment of Patient Outcomes and Satisfaction. (NCT00263107) | University of California, Davis | 2004-08-01 |
| Implant and External Radiation for Prostate Cancer With or Without Hormonal Therapy: A Prospective Randomized Trial (NCT00243646) | Schiffler Cancer Center | 2004-08-01 |
| Adjuvant Docetaxel and Estramustine Phosphate for High Risk Localized Prostate Cancer (NCT00193271) | SCRI Development Innovations, LLC | 2004-08-01 |
| CHESS Caregivers Study: Web-based Support for Informal Caregivers in Cancer (NCT00214162) | University of Wisconsin, Madison | 2004-08-01 |
| AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Androgen-Deprivation Therapy for Non-metastatic Prostate Cancer (NCT00089674) | Amgen | 2004-08-01 |
| Soy Derivatives for Control of Hot Flashes in Men on Androgen Deprivation Therapy (NCT00594620) | University of Kansas Medical Center | 2004-08-01 |
| Prostate Cancer Screening: Fostering Informed Decisions (NCT00196807) | Georgetown University | 2004-08-01 |
| Docetaxel, Doxorubicin, and Prednisone in Treating Patients With Advanced Prostate Cancer That Has Not Responded to Hormone Therapy (NCT00416533) | Wake Forest University Health Sciences | 2004-08-01 |
| Treatment With Radiolabeled Monoclonal Antibody HuJ591-GS (177Lu-J591) in Patients With Metastatic Prostate Cancer (NCT00195039) | Weill Medical College of Cornell University | 2004-08-01 |
| Radiation Therapy in Treating Patients With Stage II or Stage III Prostate Cancer (NCT00091390) | Radiation Therapy Oncology Group | 2004-07-01 |
| Bi-Weekly Administration of Docetaxel for Older Men With Hormone Refractory Prostate Cancer (NCT00215709) | Geriatric Oncology Consortium | 2004-07-01 |
| Hormone Ablation Therapy, Doxorubicin, and Zoledronate With or Without Strontium 89 in Treating Patients With Androgen-Dependent Prostate Cancer and Bone Metastases (NCT00081159) | M.D. Anderson Cancer Center | 2004-07-01 |
| ZD4054 (Zibotentan) in Pain-free or Mildly Symptomatic Patients With Prostate Cancer and Bone Metastases Who Have Rising Serum Prostate Specific Antigen (PSA) (NCT00090363) | AstraZeneca | 2004-07-01 |
| GVAX® Vaccine for Prostate Cancer vs Docetaxel & Prednisone in Patients With Metastatic Hormone-Refractory Prostate Cancer (NCT00089856) | Cell Genesys | 2004-07-01 |
| Epirubicin and Docetaxel in Treating Patients With Metastatic Prostate Cancer (NCT00096304) | Medical University of South Carolina | 2004-06-08 |
| The Plenaxis® Experience Study (NCT00103623) | PRAECIS Pharmaceuticals Inc. | 2004-06-01 |
| Phase II Trial of Stereotactic Radiosurgery Boost Following Surgical Resection for Brain Metastases (NCT00587964) | Memorial Sloan Kettering Cancer Center | 2004-06-01 |
| Long Acting LHRH Versus Short Acting LHRH in the Treatment of Prostate Cancer (NCT00175383) | University of British Columbia | 2004-06-01 |
| A Randomized Study of Testosterone Replacement in Patients With Low Risk Hormone Refractory Prostate Cancer (NCT01187485) | University of Chicago | 2004-06-01 |
| The Use of Zoledronic Acid in Men on Androgen Deprivation Therapy for Prostate Cancer With Preexisting Osteoporosis (NCT00171639) | Novartis Pharmaceuticals | 2004-06-01 |
| Fulvestrant in Treating Patients With Recurrent Prostate Cancer (NCT00217464) | Roswell Park Cancer Institute | 2004-06-01 |
| Mindfulness Relaxation Compared With Relaxing Music and Standard Symptom Management Education in Treating Patients Who Are Undergoing Chemotherapy For Newly Diagnosed Solid Tumors (NCT00086762) | M.D. Anderson Cancer Center | 2004-06-01 |
| Cancer Localization in the Prostate With F-18 Fluorocholine Positron Emission Tomography (NCT01310192) | Queen's Medical Center | 2004-06-01 |
| Study of Irofulven in Patients With Hormone-refractory Prostate Cancer (NCT00124566) | Eisai Inc. | 2004-06-01 |
| Biological Imaging for Optimising Clinical Target Volume (CTV) and Gross Tumour Volume (GTV) Contouring in Prostate Cancer to Improve the Possibilities for Intensity Modulated RadioTherapy (IMRT) Dose Escalation (NCT00122252) | Alberta Health services | 2004-05-01 |
| Green Tea Extract and Prostate Cancer (NCT00676780) | Louisiana State University Health Sciences Center Shreveport | 2004-05-01 |
| Trial to Evaluate Radiotherapy Followed by Endocrine Therapy Vs Endocrine Therapy Alone for PSA Failure After Radical Prostatectomy (NCT00138008) | Haruhiko Fukuda | 2004-05-01 |
| Family History in Prostate Cancer Patients in Taiwan (NCT00155025) | National Taiwan University Hospital | 2004-05-01 |
| Amifostine in Treating Peripheral Neuropathy Caused by Paclitaxel in Patients With Solid Tumors (NCT00078845) | M.D. Anderson Cancer Center | 2004-05-01 |
| Weekly Docetaxel and Bortezomib in the Treatment of Advanced Hormone-Refractory Prostate Cancer (NCT00193232) | SCRI Development Innovations, LLC | 2004-05-01 |
| Calcitriol in Preventing Prostate Cancer in Patients With Prostatic Intraepithelial Neoplasia (NCT00118066) | Rutgers, The State University of New Jersey | 2004-05-01 |
| Androgen Suppression Combined With Elective Nodal and Dose Escalated Radiation Therapy (NCT00175396) | University of British Columbia | 2004-05-01 |
| Study of Abarelix in Androgen-Independent Prostate Cancer Progressing After Agonist Therapy (NCT00100243) | PRAECIS Pharmaceuticals Inc. | 2004-05-01 |
| Identification of Predictive Factors for Survival of Patients With Recurrent Prostate Cancer From Clinical Features, Tissue Image Features and Molecular Biomarker Data (NCT00578409) | Memorial Sloan Kettering Cancer Center | 2004-05-01 |
| Effects of GCP on Prostate Cancer. (NCT00269555) | University of California, Davis | 2004-05-01 |
| Docetaxel and Erlotinib in Treating Older Patients With Prostate Cancer (NCT00087035) | Jonsson Comprehensive Cancer Center | 2004-05-01 |
| Magnetic Resonance Imaging to Locate and Characterize Prostate Cancer (NCT00082147) | National Cancer Institute (NCI) | 2004-04-29 |
| Archive Prostate. Observational Study of Patients Who Underwent Radical Prostatectomy Surgery (NCT06154499) | IRCCS San Raffaele | 2004-04-08 |
| Ketoconazole, Hydrocortisone, and GM-CSF in Treating Patients With Progressive Prostate Cancer After Hormone Therapy (NCT00309894) | University of California, San Francisco | 2004-04-01 |
| PR.7 Companion Trial: Effect of Intermittent Versus Continuous Androgen Suppression on Bone Loss and Body Composition (NCT00228124) | Ontario Cancer Research Network | 2004-04-01 |
| Chemotherapy, Hormone Therapy, and Surgery to Remove the Prostate Gland in Patients With High Risk Prostate Cancer (NCT00108290) | US Department of Veterans Affairs | 2004-04-01 |
| Docetaxel With or Without Oblimersen in Treating Patients With Hormone-Refractory Adenocarcinoma (Cancer) of the Prostate (NCT00085228) | European Organisation for Research and Treatment of Cancer - EORTC | 2004-04-01 |
| Robotic Laparoscopic Radical Prostatectomy (NCT00292019) | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 2004-03-04 |
| Study for Patients Who Have Benefited and Tolerated Prior Panitumumab Treatment (NCT00425204) | Amgen | 2004-03-01 |
| Docetaxel, Estramustine and Short Term Androgen Withdrawal for Patients With a Rising PSA After Local Treatment (NCT00165399) | Dana-Farber Cancer Institute | 2004-03-01 |
| Everolimus and Gefitinib in Treating Patients With Progressive Glioblastoma Multiforme or Progressive Metastatic Prostate Cancer (NCT00085566) | Memorial Sloan Kettering Cancer Center | 2004-03-01 |
| Study of Individualized Amonafide to Treat Prostate Cancer (NCT00087854) | Xanthus Pharmaceuticals, Inc. | 2004-03-01 |
| Docetaxel, Estramustine, and Thalidomide in Treating Patients With Androgen-Independent Metastatic Adenocarcinoma of the Prostate (NCT00083005) | National Institutes of Health Clinical Center (CC) | 2004-03-01 |
| Study of CEP-701 in Treatment of Prostate Cancer (NCT00081601) | Cephalon | 2004-03-01 |
| Internet-based System for Cancer Patients to Self-report Toxicity (NCT00578006) | Memorial Sloan Kettering Cancer Center | 2004-03-01 |
| Trilostane for Androgen-Independent Prostate Cancer (NCT00181597) | Genzyme, a Sanofi Company | 2004-03-01 |
| A Placebo-controlled Phase II Study of Bone-targeted Radium-223 in Symptomatic Hormone-refractory Prostate Cancer (NCT00459654) | Bayer | 2004-02-01 |
| Mathematical Modeling Analysis of Serum Prostate Specific Antigen After Radiotherapy (NCT00126815) | AHS Cancer Control Alberta | 2004-02-01 |
| Dose Finding Trial With a New Treatment (Degarelix) for Prostate Cancer (NCT00819156) | Ferring Pharmaceuticals | 2004-02-01 |
| Proton Beam Radiation Therapy for Early Stage Adenocarcinoma of the Prostate (NCT00585962) | Massachusetts General Hospital | 2004-02-01 |
| A Parallel Group Comparison of the Efficacy and Safety of Degarelix at Two Different Dosing Regimens in Patients With Prostate Cancer (NCT00116779) | Ferring Pharmaceuticals | 2004-02-01 |
| Urology Database to Evaluate Clinical Information and Improve Patient Care. (NCT00376298) | Kenneth Peters, MD | 2004-02-01 |
| Effects of Octreotide Acetate on Circulating Levels of Chromogranin A in Advanced Prostate Cancer Patients (NCT00166725) | Novartis | 2004-02-01 |
| Eligibility Screening for the NIH Intramural Research Program Clinical Protocols (NCT00026754) | National Cancer Institute (NCI) | 2004-01-14 |
| Combined, Intensified and Modulated Adjuvant Therapy in Prostate Carcinoma (NCT03169933) | IRCCS Azienda Ospedaliero-Universitaria di Bologna | 2004-01-02 |
| Experiences With HDR-brachytherapy in Norway (NCT03162523) | Oslo University Hospital | 2004-01-01 |
| A Phase 2 Study of Trabectedin (Yondelis) in Adult Male Participants With Advanced Prostate Cancer (NCT00072670) | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2004-01-01 |
| ABT-751 in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy (NCT00471718) | Vanderbilt-Ingram Cancer Center | 2004-01-01 |
| Finasteride and Flutamide in Pre-surgical Trial in Prostate Cancer. (NCT06601205) | Ente Ospedaliero Ospedali Galliera | 2004-01-01 |
| Prostate Cancer Utilities and Cost-Effectiveness Analysis (NCT00203918) | University of Chicago | 2004-01-01 |
| Radiolabeled Monoclonal Antibody in Treating Patients With Progressive Metastatic Androgen-Independent Adenocarcinoma (Cancer) of the Prostate (NCT00081172) | Memorial Sloan Kettering Cancer Center | 2004-01-01 |
| Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases (NCT00079001) | Alliance for Clinical Trials in Oncology | 2004-01-01 |
| Gefitinib and Etoposide in Treating Patients With Advanced Prostate Cancer That Did Not Respond to Hormone Therapy (NCT00483561) | University of Nebraska | 2004-01-01 |
| Trial of Docetaxel-samarium in Patients With Hormone-refractory Advanced Prostate Cancer (NCT00126230) | Gustave Roussy, Cancer Campus, Grand Paris | 2004-01-01 |
| Effects of N-Methyl-D-Aspartate (NMDA)-Receptor Antagonism on Hyperalgesia, Opioid Use, and Pain After Radical Prostatectomy (NCT00188383) | University Health Network, Toronto | 2004-01-01 |
| Study of Taxotere and Doxil to Treat Advanced Androgen-Independent Prostate Cancer (NCT00456989) | University of Louisville | 2004-01-01 |
| Lycopene in Treating Patients With Metastatic Prostate Cancer (NCT00068731) | Alliance for Clinical Trials in Oncology | 2004-01-01 |
| Dissemination of Prostate Cancer Screening to PCP's in African American Communities (NCT00629330) | Columbia University | 2004-01-01 |
| A Study of Docetaxel Plus Carboplatin in Patients With Hormone Refractory Prostate Cancer (NCT00134706) | Dana-Farber Cancer Institute | 2004-01-01 |
| Intensity-Modulated Radiation Therapy With or Without Decreased Radiation Dose to Erectile Tissue in Treating Patients With Stage II Prostate Cancer (NCT00084552) | Fox Chase Cancer Center | 2003-12-11 |